SER
Serina Therapeutics, Inc.
$2.00
-0.17 (-7.83%)
At close · Jul 8
Market Cap
$32.99M
Shares
14,997,505
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.00
Open$2.16
Day$1.95–2.21
52W$1.22–7.92
Avg vol 30d113K
Short int384K · 2.6% float · 2.1d
Short vol57%
DataJan 2020–Jul 2026
Filing10-Q · May 14
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−29%
below
Price vs 50-day avg
+9%
above
RSI (14)
54
neutral
MACD trend
Positive
52-week position
12%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+5%
trailing
6-month return
−19%
trailing
YTD return
+5%
this year
Relative strength
−26%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
+14% holders QoQ · +10 funds added
Insider flow
Accumulating
Net +$77.9K over 90 days · 0% sells
Short interest
Rising
2.56% of float · ▲ +11.3% MoM · 2.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
25 holders — mid 2-yr range
Squeeze score
57
elevated · 0–100
Fundamentals
Revenue growth
+132%
Y/Y
Gross margin
78%
expanding
EPS growth
−26%
Y/Y
Free cash flow
$-18.0M
Balance sheet
$15.1M
net debt
Quant / Vol
risk profile
Volatility
137%
annualized · 1-yr
Max drawdown
−79%
past year
ATR
9.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−29%
Bearish
Price vs 50-day avg
+9%
Bullish
RSI (14)
54
Neutral
MACD trend
Positive
Bullish
52-week position
12%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
+14% holders QoQ · +10 funds added
Insider flow
Accumulating
Net +$77.9K over 90 days · 0% sells
Short interest
Rising
2.56% of float · ▲ +11.3% MoM · 2.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
25 holders — mid 2-yr range
Price context
position in its 52-week range
52-wk low $1
Now $2 · 12%
52-wk high $8
vs 200-day avg -29%
vs 50-day avg +9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SER
this stock
Serina Therapeutics, Inc.
|
$32.99M | +4.5% | +132.1% | — | 2.6% |
|
ONC
BeOne Medicines Ltd.
|
$436.30B | -0.6% | +22179.2% | 887.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.50B | +9.9% | +46.2% | 29.6 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.50B | -14.0% | +20.8% | 16.2 | 3.2% |
|
ARGX
Argenx SE
|
$57.20B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SER | +3.1% | +5.3% | -18.7% | +3.1% | +4.6% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +3.3% | +4.4% | -26.1% | +3.3% | -4.8% |